Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC).

被引：0

作者：

Greystoke, Alastair

Oughton, Jamie B.

Brown, Sarah R.

Butterworth, Karl

Coyle, Victoria

Franks, Kevin

Hassani, Adam

Harrow, Stephen

Hatton, Matthew

Hiley, Crispin T.

Kendall, Jessica

Phillip, Rachel

Norris, Matthew

Ojo, Oluwaseun

Shaw, Paul

Walker, Fiona

Yang, Huiqi

Chalmers, Anthony J.

Faivre-Finn, Corinne

机构：

[1] Univ Newcastle, Northern Ctr Canc Care, Newcastle Upon Tyne, England

[2] Univ Leeds, Leeds Inst Clin Trials Res, Leeds, England

[3] Queens Univ Belfast, Belfast, North Ireland

[4] Leeds Teaching Hosp NHS Trust, Leeds, England

[5] Northern Ctr Canc Care, Newcastle Upon Tyne, England

[6] Edinburgh Canc Ctr, Western Gen Hosp, Edinburgh, Scotland

[7] Weston Pk Hosp, Sheffield, England

[8] Univ Coll Hosp London, London, England

[9] AstraZeneca, Cambridge, England

[10] Velindre Canc Ctr, Cardiff, Wales

[11] Cambridge Univ Hosp, Cambridge, England

[12] Univ Glasgow, Glasgow, Scotland

[13] Christie NHS Fdn Trust, Manchester, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8119

引用

页数：1

共 50 条

[1] CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in non-small cell lung cancer (NSCLC)
Horne, Ashley
Ali, Aaisha
Brown, Sarah
Butterworth, Karl
Chalmers, Anthony
Clipson, Alexandra
Collinson, Fiona
Dive, Caroline
Faivre-Finn, Corinne
Forster, Martin
Franks, Kevin
Gilbert, Alexandra
Hanna, Gerry
Hannaway, Nicola
Harrow, Stephen
Hartley, John
Hiley, Crispin
Jones, Robert
Kendall, Jessica
Krebs, Matthew
Mallison, Georgia
O'Connor, James
Oughton, Jamie
Phillip, Rachel
Rothwell, Dominic
Salem, Ahmed
Sebag-Montefiore, David
Shaw, Paul
Walls, Gerard
Young, Robin
Greystoke, Alastair
LUNG CANCER, 2022, 165 : S69 - S70
[2] CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC)
Horne, A.
Brown, S.
Butterworth, K.
Chalmers, A.
Collinson, F.
Dive, C.
Faivre-Finn, C.
Forster, M.
Franks, K.
Gilbert, A.
Hallam, M.
Hanna, G.
Harrow, S.
Hartley, J.
Hiley, C.
Jones, R.
Katona, E.
Kendall, J.
Krebs, M.
Mallison, G.
Oughton, J. B.
Phillip, R.
Rothwell, D.
Sebag-Montefiore, D.
Shaw, P.
Walls, G.
Walker, F.
Young, R.
Greystoke, A.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S267 - S268
[3] CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
Walls, Gerard M.
Oughton, Jamie B.
Chalmers, Anthony J.
Brown, Sarah
Collinson, Fiona
Forster, Martin D.
Franks, Kevin N.
Gilbert, Alexandra
Hanna, Gerard G.
Hannaway, Nicola
Harrow, Stephen
Haswell, Tom
Hiley, Crispin T.
Hinsley, Samantha
Krebs, Matthew
Murden, Geraldine
Phillip, Rachel
Ryan, Anderson J.
Salem, Ahmed
Sebag-Montefoire, David
Shaw, Paul
Twelves, Chris J.
Walker, Katrina
Young, Robin J.
Faivre-Finn, Corinne
Greystoke, Alastair
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2020, 25 : 61 - 66
[4] Boosting immune response with copanlisib in locally advanced unresectable non-small cell lung cancer starting durvalumab consolidation: A phase Ib study
Hao, Z.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S114 - S115
[5] A phase 1 trial of the MEK1/2 inhibitor AZD6244 in combination with thoracic radiotherapy in advanced non-small cell lung cancer (NSCLC)
Koh, R. Keng
Califano, R.
Dean, E.
Kosmin, J.
Ataman, O.
Jackson, A.
Blackhall, F. H.
Faivre-Finn, C.
LUNG CANCER, 2010, 67 : S33 - S34
[6] Phase Ib study of sintilimab in combination with chemotherapy for 1L advanced or metastatic non-small cell lung cancer (NSCLC).
Xu, Nong
Ying, Kejing
Wang, Ziping
Liu, Yunpeng
Jiang, Haiping
Zhou, Hui
Wang, Shuyan
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC)
Theriau, Christopher F.
Feng, Jamie
Eng, Lawson
Shepherd, Frances A.
DeCarolis, Mary
Glenns, Vivian
Kulkarni, Swati
VanderMeer, Rachel
Zurawska-Fortin, Urszula
Hao, Desiree
Le, Lisa
Wozniczka, Isabel
Al-Kindy, Aida
Xie, Danny
Zhang, Tong
Subramanian, Vasanth
Stockley, Tracy
Bradbury, Penelope A.
Liu, Geoffrey
Leighl, Natasha B.
CANCER RESEARCH, 2023, 83 (08)
[8] Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer
de Haan, Rosemarie
van den Heuvel, Michel M.
van Diessen, Judi
Peulen, Heike M. U.
van Werkhoven, Erik
de Langen, Adrianus J.
Lalezari, Ferry
Pluim, Dick
Verwijs-Janssen, Manon
Vens, Conchita
Schellens, Jan H. M.
Steeghs, Neeltje
Verheij, Marcel
van Triest, Baukelien
CLINICAL CANCER RESEARCH, 2021, 27 (05) : 1256 - 1266
[9] A PHASE 2 STUDY OF DURVALUMAB COMBINED WITH CHEMOTHERAPY AND STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN PATIENTS WITH OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) (SABRCURE TRIAL)
Chen, Ming
Ma, Honglian
Du, Xianghui
Xu, Yujin
Ji, Yongling
Song, Zhengbo
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A729 - A729
[10] Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC).
Raftopoulos, Harry
Aisner, Joseph
Kumar, Kirushna
Goel, Sanjay
Dittrich, Christian
Jain, Minish
Gopalakrishna, Prashanth
Salazar, Paloma
Jones, Beverley
Petrylak, Daniel Peter
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →